Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

authors

• Ruppert Anne-Marie
• Beau-Faller Michèle
• Debieuvre Didier
• Ouafik L'Houcine
• Westeel Virginie
• Rouquette Isabelle
• Mazières Julien
• Bringuier Pierre-Paul
• Monnet Isabelle
• Escande Fabienne
• Ricordel Charles
• Merlio Jean-Philippe
• Janicot Henri
• Lemoine Antoinette
• Foucher Pascal
• Poudenx Michel
• Morin Franck
• Langlais Alexandra
• Souquet Pierre-Jean
• Barlesi Fabrice
• Wislez Marie

keywords

• KRAS mutation
• Non-small cell lung cancer
• NSCLC
• Prognosis

abstract

Introduction - Methods - In the Biomarkers France study, 4894 mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the mutations subtype. Results - Over 95% of patients with mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common mutation subtype was G12C (374 patients; 41.5%), followed by G12V (168; 18.6%), G12D (131; 14.5%), G12A (62; 6.9%), G13C (45; 5.0%), G13D (31; 3.4%), and others (10; 1%). Approximately 21% of patients had transition mutation and 68.2% had a transversion mutation. G12D and transition mutations were predominant in never-smokers. The median overall survival for patients with -mutated NSCLC was 8.1 months (95% confidence interval [CI]: 7.5-9.5), without any differences according to the different subtypes mutations. The median progression-free survival was 4.6 months (95% CI: 4.2-5.1) for first-line treatment and 4.8 months (95% CI: 4.3-6.8) for second-line treatment, without any differences according to the different subtypes mutations. Conclusions

more information